SEMA3C and metabolic dysfunction-associated steatohepatitis: In the future, different liver cancer models will be used to verify the role of Sema3C in diverse etiologies of HCC, such as the hydrokinetic tail vein (HTV) -NRasV12+Myr-AKT proto-oncogene driven HCC tumors and non-alcoholic steatohepatitis (NASH)-HCC mouse models.